Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of 125.74 million. The enterprise value is 145.43 million.
| Market Cap | 125.74M |
| Enterprise Value | 145.43M |
Important Dates
The next estimated earnings date is Friday, January 23, 2026.
| Earnings Date | Jan 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 94.99M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 3.86% |
| Owned by Institutions (%) | 0.23% |
| Float | 41.91M |
Valuation Ratios
The trailing PE ratio is 13.21 and the forward PE ratio is 10.46.
| PE Ratio | 13.21 |
| Forward PE | 10.46 |
| PS Ratio | 1.61 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 1.69 |
| P/FCF Ratio | 12.65 |
| P/OCF Ratio | 8.63 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.09, with an EV/FCF ratio of 14.63.
| EV / Earnings | 15.28 |
| EV / Sales | 1.88 |
| EV / EBITDA | 7.09 |
| EV / EBIT | 9.28 |
| EV / FCF | 14.63 |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.41.
| Current Ratio | 2.40 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 1.47 |
| Debt / FCF | 3.05 |
| Interest Coverage | 5.75 |
Financial Efficiency
Return on equity (ROE) is 13.75% and return on invested capital (ROIC) is 9.67%.
| Return on Equity (ROE) | 13.75% |
| Return on Assets (ROA) | 8.37% |
| Return on Invested Capital (ROIC) | 9.67% |
| Return on Capital Employed (ROCE) | 16.11% |
| Revenue Per Employee | 172,641 |
| Profits Per Employee | 21,058 |
| Employee Count | 452 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.32 |
Taxes
In the past 12 months, Cannara Biotech has paid 3.65 million in taxes.
| Income Tax | 3.65M |
| Effective Tax Rate | 27.74% |
Stock Price Statistics
The stock price has increased by +146.30% in the last 52 weeks. The beta is 0.32, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +146.30% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 55.93 |
| Average Volume (20 Days) | 9,234 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of 78.03 million and earned 9.52 million in profits. Earnings per share was 0.10.
| Revenue | 78.03M |
| Gross Profit | 34.29M |
| Operating Income | 15.77M |
| Pretax Income | 13.17M |
| Net Income | 9.52M |
| EBITDA | 20.43M |
| EBIT | 15.77M |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
The company has 10.45 million in cash and 30.27 million in debt, with a net cash position of -19.81 million.
| Cash & Cash Equivalents | 10.45M |
| Total Debt | 30.27M |
| Net Cash | -19.81M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 74.41M |
| Book Value Per Share | 0.81 |
| Working Capital | 34.91M |
Cash Flow
In the last 12 months, operating cash flow was 14.57 million and capital expenditures -4.63 million, giving a free cash flow of 9.94 million.
| Operating Cash Flow | 14.57M |
| Capital Expenditures | -4.63M |
| Free Cash Flow | 9.94M |
| FCF Per Share | n/a |
Margins
Gross margin is 43.94%, with operating and profit margins of 20.20% and 12.20%.
| Gross Margin | 43.94% |
| Operating Margin | 20.20% |
| Pretax Margin | 16.88% |
| Profit Margin | 12.20% |
| EBITDA Margin | 26.18% |
| EBIT Margin | 20.20% |
| FCF Margin | 12.74% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.08% |
| Shareholder Yield | -1.08% |
| Earnings Yield | 7.57% |
| FCF Yield | 7.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 2.35 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.35 |
| Piotroski F-Score | 7 |